A HIGHLY SELECTIVE AND SENSITIVE LC-MS/HRMS ASSAY FOR COPORPORPHYRIN-I AND -III, EMERGING ENDOGENOUS BIOMARKERS OF OATP, IN FIRST-IN-HUMAN CLINICAL TRIALS

摘要

The evaluation of transporter biomarkers in early clinical trials could help identify NCE candidates with true drug-drug interaction (DDI) liabilities and thus reduce the number of costly clinical DDI studies being conducted. Coproporphyrin-I and Coproporphyrin-III are two such endogenous isomeric compounds which have emerged as potentially viable biomarkers of organic anion transporting polypeptide (OATP) mediated DDIs.